8. Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes: Standards of Care in Diabetes–2025
Open accessThe DOI matches its Crossref record; 156 of the 157 references it cites were found in a registry or an index.
Abstract
The American Diabetes Association (ADA) “Standards of Care in Diabetes” includes the ADA’s current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, an interprofessional expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA’s clinical practice recommendations and a full list of Professional Practice Committee members, please refer to Introduction and Methodology. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“physical activity plays an indispensable role”
From Lifestyle Medicine for Obesity in the Era of Highly Effective Anti-Obesity Treatment (2025) · cites this paper as [53]
In the citing paper
“Evidence-based dietary management is the cornerstone of T2DM prevention and control, as it can effectively improve glycemic control and even achieve disease remission (2).”
In the citing paper
“Those with obesity who have engaged in some form of calorie or dietary restriction have a higher likelihood of developing nutritional deficiencies [53,98,99,130,131]”
From Lifestyle Medicine for Obesity in the Era of Highly Effective Anti-Obesity Treatment (2025) · cites this paper as [53]
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
(2004) · The Lancet · doi:10.1016/s0140-6736(03)15268-3 · Cited by 12,717
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Self-citationEffects of Bariatric Surgery on Mortality in Swedish Obese Subjects
Sjöström, L., Narbro, K., Sjöström, C. D., Karason, K., Larsson, B., Wedel, H., Lystig, T., Sullivan, M., Bouchard, C., Carlsson, B., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066254 · Cited by 4,668
Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery
Sjöström, L., Lindroos, A.-K., Peltonen, M., Torgerson, J., Bouchard, C., Carlsson, B., Dahlgren, S., Larsson, B., Narbro, K., Sjöström, C. D., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa035622 · Cited by 4,457
2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults
Jensen, M. D., Ryan, D. H., Apovian, C. M., Ard, J. D., Comuzzie, A. G., Donato, K. A., Hu, F. B., Hubbard, V. S., Jakicic, J. M., Kushner, R. F., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.004 · Cited by 4,058
Self-citation2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Colvin, M. M., Drazner, M. H., Filippatos, G. S., Fonarow, G. C., Givertz, M. M., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.04.025 · Cited by 3,418
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236
Self-citationBariatric Surgery versus Intensive Medical Therapy for Diabetes — 5-Year Outcomes
Schauer, P. R., Bhatt, D. L., Kirwan, J. P., Wolski, K., Aminian, A., Brethauer, S. A., Navaneethan, S. D., Singh, R. P., Pothier, C. E., Nissen, S. E., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1600869 · Cited by 2,934
Research works printed but not linked: 2
- Steven, 2016, Very low-calorie diet and 6 months of weight stability in type 2 diabetes: pathophysiological changes in responders and nonresponders. Diabetes Care 2016;39:808–815, Diabetes Care, 41, 1321
- American Medical Association . Person-First Language for Obesity H-440.821. Accessed 21 August 2024. Available from https://policysearch.ama-assn.org/policyfinder/detail/obesity?uri=%2FAMADoc%2FHOD.xml-H-440.821.xml
Cited by
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236
Self-citationLingvay, I., Cohen, R. V., Roux, C. W. L., & Sumithran, P. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01210-8 · Cited by 433
Self-citationCusi, K., Abdelmalek, M. F., Apovian, C. M., Balapattabi, K., Bannuru, R. R., Barb, D., Bardsley, J. K., Beverly, E. A., Corbin, K. D., ElSayed, N. A., et al. (2025) · Diabetes Care · doi:10.2337/dci24-0094 · Cited by 332
Self-citationCagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes
Davies, M. J., Bajaj, H. S., Broholm, C., Eliasen, A., Garvey, W. T., le Roux, C. W., Lingvay, I., Lyndgaard, C. B., Rosenstock, J., & Pedersen, S. D. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2502082 · Cited by 143
Self-citationNadolsky, K., Garvey, W. T., Agarwal, M., Bonnecaze, A., Burguera, B., Chaplin, M. D., Griebeler, M. L., Harris, S. R., Schellinger, J. N., Simonetti, J., et al. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.07.017 · Cited by 141
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes
Rosenstock, J., Hsia, S., Nevarez Ruiz, L., Eyde, S., Cox, D., Wu, W.-S., Liu, R., Li, J., Fernández Landó, L., Denning, M., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2505669 · Cited by 132
Sattar, N., Neeland, I. J., Dahlqvist Leinhard, O., Fernández Landó, L., Bray, R., Linge, J., & Rodriguez, A. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00027-0 · Cited by 131
Ndumele, C. E., Rodríguez, F., Dixon, D. L., Khan, S. S., Mukherjee, D., Bajaj, M. S., Bangalore, S., Bozkurt, B., Breathett, K. K., Clarke, S. L., et al. (2026) · Circulation · doi:10.1161/cir.0000000000001453 · Cited by 151
Self-citationNdumele, C. E., Rodriguez, F., Dixon, D. L., Khan, S. S., Mukherjee, D., Bajaj, M., Bangalore, S., Bozkurt, B., Breathett, K., Clarke, S. L., et al. (2026) · JACC · doi:10.1016/j.jacc.2026.03.056 · Cited by 90
Self-citationDiabetes and its complications: molecular mechanisms, prevention and treatment
Zhao, L., Yuan, J., Yang, Q., Ma, J., Yang, F., Zou, Y., Liu, K., & Liu, F. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02401-w · Cited by 80
de Mesquita, Y. L. L., Pera Calvi, I., Reis Marques, I., Almeida Cruz, S., Padrao, E. M. H., Carvalho, P. E. D. P., da Silva, C. H. A., Cardoso, R., Moura, F. A., & Rafalskiy, V. V. (2023) · International Journal of Obesity · doi:10.1038/s41366-023-01337-x · Cited by 59
Coskun, T., Wu, Q., Schloot, N. C., Haupt, A., Milicevic, Z., Khouli, C., & Harris, C. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00092-0 · Cited by 57
Gigliotti, L., Warshaw, H., Evert, A., Dawkins, C., Schwartz, J., Susie, C., Kushner, R., Subramanian, S., Handu, D., & Rozga, M. (2025) · Journal of the Academy of Nutrition and Dietetics · doi:10.1016/j.jand.2024.10.023 · Cited by 53
Self-citationMarassi, M., Cignarella, A., Russo, G. T., Nollino, L., Strazzabosco, M., Marzullo, P., Leonetti, F., Avogaro, A., Consoli, A., & Fadini, G. P. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107866 · Cited by 38
Lifestyle Medicine for Obesity in the Era of Highly Effective Anti-Obesity Treatment
Sannidhi, D., Abeles, R., Andrew, W., Bonnet, J. P., Vitale, K., Niranjan, V., Gulati, M., Pauly, K., Moran, R., Alexander, L., et al. (2025) · Nutrients · doi:10.3390/nu17142382 · Cited by 29
“- Requires medical supervision; risk of nutrient deficiency, gallstones, electrolyte abnormalities, severe fatigue, and arrhythmias [53,179].”
InfluentialLifestyle Interventions in Cardiovascular-Kidney-Metabolic Syndrome JACC: Advances Expert Panel
Shahid, I., Philip, J. S., Avenatti, E., Laddu, D., Shapiro, M. D., Khera, A., Pandey, A., Ndumele, C. E., Gulati, M., Nasir, K., et al. (2025) · JACC Advances · doi:10.1016/j.jacadv.2025.101788 · Cited by 32
Diabetes Remission After Bariatric Surgery: A 10-Year Follow-Up Study
Meira, I., Menino, J., Ferreira, P., Leite, A. R., Gonçalves, J., Ferreira, H. U., Ribeiro, S., Moreno, T., Silva, D. F., Pedro, J. M. P., et al. (2024) · Obesity Surgery · doi:10.1007/s11695-024-07592-9 · Cited by 31
Endocrine and metabolic effects of GLP-1 receptor agonists on women with PCOS, a narrative review
Monney, M., Mavromati, M., Leboulleux, S., & Gariani, K. (2025) · Endocrine Connections · doi:10.1530/ec-24-0529 · Cited by 30
“Weight loss is a cornerstone in the therapeutic management of many cases of PCOS (5, 42).”
Kałas, M., Stępniewska, E., Gniedziejko, M., Leszczyński-Czeczatka, J., & Siemiński, M. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14093122 · Cited by 24
“As far as obesity is concerned, GLP-ARs are approved for patients with a Body Mass Index (BMI) > 30 or BMI > 27 and at least one weight-related complication, such as elevated blood pressure, hyperlipidemia, or DMT2, in addition to increased physical activity and reduced calorie diet [20].”
GLP-1-based therapeutics for cardiorenal protection in metabolic diseases
Apperloo, E. M., Heerspink, H. J. L., van Raalte, D. H., & Muskiet, M. H. A. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaf110 · Cited by 25
“In T2D, recognition that double-digit weight loss has substantial benefits (e.g. T2D remission) further shifted guidelines to prioritize weight management, alongside CV risk reduction and glycaemic control [6 ].”
Majanović, S. K., Belančić, A., Bukša, I., Morić, N., & Rahelić, D. (2024) · Diabetology · doi:10.3390/diabetology5010005 · Cited by 23
Obesity and its management in primary care setting
Ibrahim, M. A., Ba-Essa, E. M., Alvarez, J. A., Baker, J. C., Bruni, V., Cahn, A., Ceriello, A., Cosentino, F., Davies, M. J., Domenico, F. D., et al. (2025) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2025.109045 · Cited by 21
Self-citationKhani, M., Afsahi, R., Nasab, A. E., Bi’aragh, S. H., Rasouli, K., Ahangar, M. H., Soltani, A., & Pourahmad, R. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01925-z · Cited by 23
“This reframes AOMs from short-term aids to long-term, disease-modifying agents [14, 15].”
The Close Link Between Obesity and Cardiovascular Disease
Lee, H., Rhee, T., Choi, J. M., Choi, S., & Kim, D. W. (2025) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2024.10.005 · Cited by 18
Wong, H. J., Lin, N., Teo, Y. H., Yeo, B. S. Y., Toh, K. Z. X., Teo, Y. N., Chan, M. Y., Yeo, L. L. L., Poh, K. K., Kong, W. K. F., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16136 · Cited by 20
Hankosky, E. R., Lebrec, J., Lee, C. J., Dimitriadis, G. K., Jouravskaya, I., Stefanski, A., & Garvey, W. T. (2025) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.70143 · Cited by 17
“14,15 To achieve these goals, clinical guidelines recommend treatment with obesity management medications as an adjunct to lifestyle interventions for people with obesity (body mass index [BMI] ≥ 30 kg/m 2 ) or overweight (BMI ≥ 27 kg/m 2 ) and at least one obesity-related complication.”
Havers, T., Held, S., Schönfelder, M., Geisler, S., & Wackerhage, H. (2025) · Sports Medicine · doi:10.1007/s40279-025-02263-w · Cited by 19
Lin, W., Pu, L., Qian, X., Pan, J., Cheng, R., & Sun, P. (2025) · Frontiers in Microbiology · doi:10.3389/fmicb.2025.1671975 · Cited by 18
Causes and consequences of discontinuation of GLP1RAs or tirzepatide
Ceriello, A., Prattichizzo, F., Abdullah, A. R. M. S., Grotta, R. L., Berra, C., McGowan, B. M., Jenkins, A., Cohen, N. D., Nauck, M. A., & Russo, G. T. (2026) · Nature Reviews Endocrinology · doi:10.1038/s41574-026-01258-5 · Cited by 23
“Similarly, selected GLP1RAs and tirzepatide are indicated to promote weight loss in people with a BMI ≥30 kg/m 2 or with a BMI ≥27 kg/m 2 and at least one obesity-related complication who do not achieve adequate weight loss with lifestyle interventions 23 .”
Beyond Weight Loss: Optimizing GLP-1 Receptor Agonist Use in Children
Zaitoon, H., Wauters, A. D., Rodríguez, L. M., & Lynch, J. L. (2025) · Children · doi:10.3390/children12111427 · Cited by 15
“For optimal weight loss, interventional visits should be frequent ( ≥ 16 sessions in 6 months) [63].”
Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes
Guo, L., Zhang, B., Xue, X., Zhang, B., Cai, H., Jiang, H., Zhang, L., Jin, P., Wang, X., Cheng, Z., et al. (2025) · Nature · doi:10.1038/s41586-025-10031-z · Cited by 21
The Liver in Diabetes and Metabolic Syndrome
Mahmoud, M. C., & Abdelmalek, M. F. (2025) · Clinics in Liver Disease · doi:10.1016/j.cld.2025.04.003 · Cited by 14
Vozza, A., Triggiani, D., Fanelli, M., Lisco, G., Coletto, D., Custodero, C., Volpe, S., Racaniello, D., Colaianni, V., Lavarra, V., et al. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1674308 · Cited by 12
Adipocentric Strategy for the Treatment of Type 2 Diabetes Mellitus
Martínez, J. J. G. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14030678 · Cited by 15
Clinical Assessment of People With Obesity: Focus on Adiposity-Related Multimorbidity
Bianchettin, R. G., Gawey, B. J., Acosta, A. J., Borlaug, B. A., Caples, S. M., Collazo–Clavell, M. L., Clark, M. M., Lara-Breitinger, K. M., Lerman, A., Lerman, L. O., et al. (2025) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2025.02.021 · Cited by 16
Podder, D., Stala, O., Miah, A., Agyapong, A., Moore, M. E., Hirani, R., Diegisser, D., Garcia, V. G., & Etienne, M. (2026) · Diabetology · doi:10.3390/diabetology7030046 · Cited by 19
Luo, Y., Jiang, H., Shi, B., Cai, H., Wang, H., Li, S., Qiu, W., Li, Y., Zhou, R., Deng, H., et al. (2025) · Contemporary Clinical Trials · doi:10.1016/j.cct.2025.108150 · Cited by 10
Voziki, D., Dimakopoulos, G., Stergiou, I., Zografou, I., Rizzo, M., Liberopoulos, E. N., Kotsa, K., & Koufakis, T. (2025) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2025.109044 · Cited by 9
Vilsbøll, T., Malecki, M. T., Sharma, P., Thieu, V. T., Chivukula, K. K., & Kiljanski, J. I. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16592 · Cited by 12
Chakravarthy, M. V., Elliott, M. A., Acosta, L., Sonnenberg, G. E., Bialonczyk, D., Wu, J., ARGÜELLES-TELLO, F. A., Garcia‐Reza, R., González‐González, J. G., Hansen, S. K., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70006 · Cited by 11
Mateos, I. C., Morales, C., & Aguilera, B. G. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14155434 · Cited by 12
“…for the management of T2D have endorsed a multifactorial and holistic approach with the aim of preventing or delaying CV complications and have highlighted the clinical importance of weight reduction as a pillar of this holistic approach, thus contributing to improving glycemic control [7–10].”
Efficacy and safety of incretin co-agonists: Transformative advances in cardiometabolic healthcare
Bhat, S., Fernandez, C. J., Lakshmi, V., & Pappachan, J. M. (2025) · World Journal of Cardiology · doi:10.4330/wjc.v17.i8.107991 · Cited by 9
Orioli, L., Thissen, J.-P., & Loumaye, A. (2025) · Clinical Nutrition · doi:10.1016/j.clnu.2025.106547 · Cited by 10
Zhu, D., Wang, W., Tong, G., Ma, J., WEN, B., Zheng, X., Shi, B., Shuguang, P., Wang, K., Shi, X., et al. (2026) · Nature Communications · doi:10.1038/s41467-025-68165-7 · Cited by 9
“More importantly, at week 24, 39.1 – 43.7% in the ecnoglutide groups versus 11.3% in the placebo group achieved a bodyweight loss of ≥ 5%, meeting the ADA-recommended target range for weight loss 24 .”
InfluentialGao, L., Jiang, H. X., Cai, H., Tian, J., Shi, B., Qiu, W., Huang, C., Han, J., Suhe, Z., Pang, S., et al. (2026) · JAMA · doi:10.1001/jama.2026.8142 · Cited by 10
Fujihara, K., KHIN, L. M., Murai, K., Yamazaki, Y., Tsuruoka, K., Yagyuda, N., Yamazaki, K., Maegawa, H., Tanaka, S., Kodama, S., et al. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15206 · Cited by 10
Sadeghi, S., Hosseinpanah, F., Khalaj, A., Ebadinejad, A., Mahdavi, M., Valizadeh, M., & Barzin, M. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15974 · Cited by 11
Pharmacologic Therapies for Type 2 Diabetes
Kuo, B., & Li, J. H. (2025) · NEJM Evidence · doi:10.1056/evidra2400265 · Cited by 9
“After tirzepatide, weight loss is greatest with the maximum dose of semaglutide, followed by liraglutide and dulaglutide 19,48 .”
Ruddiman, K. R., Bartfield, J. K., & Hirsch, I. B. (2025) · Obesity · doi:10.1002/oby.70033 · Cited by 10
Vademecum for the Physician Evaluating a Master Athlete
Palermi, A., Vecchiato, M., Gioia, G. D., Perone, F., Tse, G., Gallina, S., Luca, M. D., Graziano, F., Zorzi, A., Tsampasian, V., et al. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01370-3 · Cited by 9
“Combine aerobic + resistance training (≥ 150 min/week aerobic + 2–3 resistance sessions/week) and tailor session timing and fueling to minimize hypoglycemia in in patients treated with insulin or oral hypoglycemic agents associated with risk of hypoglycemia [39, 47].”
Tang, H., Zhang, B., Lu, Y., Zhang, D., Liu, R., Lu, Y., Cotsarelis, G., Asch, D. A., & Chen, Y. (2026) · BMJ · doi:10.1136/bmj-2026-100077 · Cited by 11
Yu, X., Wang, X., Dun, S., Zhang, H., Yao, Y., Liu, Z., Wang, J., & Liu, W. (2025) · Hellenic Journal of Cardiology · doi:10.1016/j.hjc.2024.12.007 · Cited by 7
Cheng, C., Cui, H., Yu, X., & Li, W. (2025) · Foods · doi:10.3390/foods14111916 · Cited by 7
“Obesity is a major comorbidity of type 2 diabetes, and certain glucose-lowering drugs (e.g., insulin, sulfonylureas) may induce weight gain [43].”
Current treatment for diabetes: a holistic approach
Mourelatou, N. G., Kounatidis, D. C., Vallianou, N. G., Daniele, G., Dardano, A., & Rebelos, E. (2025) · HORMONES · doi:10.1007/s42000-025-00734-3 · Cited by 8
Aygun, B. B., Basturk, B., & Ayaz, A. (2026) · Current Obesity Reports · doi:10.1007/s13679-025-00684-2 · Cited by 8
“Current therapeutic options include behavioral therapy, lifestyle counsel - ing, pharmacotherapy for body weight management, and metabolic surgery [ 8].”
Zambrano-Villacres, R., Campuzano-Donoso, M., Reytor-González, C., Rossetti, G., Cobellis, L., Cobellis, F., Pilone, V., Simancas‐Racines, D., & Schiavo, L. (2026) · Nutrients · doi:10.3390/nu18111751 · Cited by 8
Pi, L., He, B., Fei, D., Shi, X., & Zhou, Z. (2024) · BMC Primary Care · doi:10.1186/s12875-024-02600-4 · Cited by 6
Evolution of multidisciplinary obesity treatments: past, present, and future role of nutrition
Heymsfield, S. B., Atherton, P. J., Christensen, S. M., Tewksbury, C. M., Velazquez, A., Walter, J., & Blaak, E. E. (2025) · Obesity · doi:10.1002/oby.24340 · Cited by 7
Adam, C. A., Popiołek-Kalisz, J., Akıncı, B., Manzi, G., Ullah, I., Beneki, E., Mitu, F., Baťalík, L., Ostojic, M., & Perone, F. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14217791 · Cited by 6
Wharton, S., le Roux, C. W., Bozkurt, B., Platz, E., Bleckert, G., Hussain, S. A., Brueckmann, M., Startseva, E., Kloer, I. M., & Kaplan, L. M. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70263 · Cited by 7
Chen, Y., Liang, X., Qi, Y., Liu, C., Dong, B., Li, X., Shen, J., Xiqiao, Z., Xuan, L., Minghua, Z., et al. (2025) · China CDC Weekly · doi:10.46234/ccdcw2025.248 · Cited by 6
Kvist, A. V., Andersen, S. S., Vestergaard, P., & Viggers, R. (2026) · Osteoporosis International · doi:10.1007/s00198-026-07950-6 · Cited by 6
Striving for early effective glycaemic and weight management in type 2 diabetes: A narrative review
CHENG, A. Y. Y., Heine, R. J., Prato, S. D., Green, J. B., Thieu, V. T., & Zeytinoglu, M. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16206 · Cited by 7
AIP, fatty liver, and HbA1c as modifiers of the C-index and diabetes risk relationship
Liu, Y., Shi, R., Cao, H., Zhang, J., Li, S., Kang, X., Ma, Y., Wu, Y., Guo, Y., & Feng, L. (2025) · Lipids in Health and Disease · doi:10.1186/s12944-025-02546-1 · Cited by 8
Wasden, K., Mathur, V., Martin, T. J., Shin, T. H., Nimeri, A. A., Tavakkoli, A., & Sheu, E. G. (2025) · Surgical Endoscopy · doi:10.1007/s00464-025-11910-2 · Cited by 10
“Additionally, the literature describes a subset of “responder” patients with early or successful weight loss with these medications, often defined as 5% TWL at around three–four months on the medication [23, 24].”
Metabolic Bariatric Surgery in Kidney Transplant Candidates
Kukla, A., COHEN, R. V., & Friedman, A. N. (2025) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2025.06.015 · Cited by 6
The association of obesity with cardiovascular disease risk and risk-enhancing factors
Paparodis, R. D., Bantouna, D., Livadas, S., & Angelopoulos, N. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.08.018 · Cited by 6
Kris‐Etherton, P. M., Petersen, K. H., Lamarche, B., Karmally, W., Guyton, J. R., Champagne, C. M., Lichtenstein, A. H., Bray, G. A., Sacks, F. M., & Maki, K. C. (2024) · Journal of clinical lipidology · doi:10.1016/j.jacl.2024.09.010 · Cited by 5
Herges, J. R., Neumiller, J. J., & McCoy, R. G. (2025) · Clinical Diabetes · doi:10.2337/cd24-0115 · Cited by 5
Self-citationPark, Y. S., Jeon, D., Shi, S., Sheu, E. G., Tavakkoli, A., Nimeri, A. A., & Han, A. (2025) · International Journal of Surgery · doi:10.1097/js9.0000000000003631 · Cited by 8
Schumacher, L. M., Bass, S. B., Ard, J. D., Rubin, D. J., Herring, S. J., Rao, A. D., Jones, R. M., & Sarwer, D. B. (2025) · Diabetes Care · doi:10.2337/dci25-0094 · Cited by 6
A Review of First-Generation Obesity Medications
Schmitz, S. H., & Saunders, K. H. (2026) · Current Atherosclerosis Reports · doi:10.1007/s11883-026-01389-0 · Cited by 5
“The American Diabetes Association Standards of Care now identify weight management as a primary goal of treatment in patients with type 2 diabetes and overweight or obesity [ 30].”
Diagnosis, staging and management of obesity: a synthesis of contemporary guidelines
Tandar, C. E., Lin, J. C., & Stanford, F. C. (2026) · Nature Reviews Endocrinology · doi:10.1038/s41574-026-01279-0 · Cited by 6
Scannell, C., O'Neill, T., & Griffin, A. (2025) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70036 · Cited by 5
“This may be an indication of the close correlation between increased adiposity and type 2 diabetes mellitus risk [25].”
InfluentialWu, B., Li, W., Xu, S., Chen, R., Ding, Y., Xu, R., Wu, Z., Bao, M., He, B., & Li, S. (2025) · Medicine · doi:10.1097/md.0000000000042998 · Cited by 6
IGUDESMAN, D. A., Nally, L. M., Grimshaw, A. A., Gunderson, C. G., Considine, E. G., Jacobsen, L. M., Tosur, M., Gottlieb, P. A., Hirsch, I. B., Laffel, L. M., et al. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf448 · Cited by 5
Yu, Y., Liu, P., Zhan, M.-W., Chen, Y.-Q., Lai, Y.-Q., Wang, L., Wu, J., Yao, F., Chen, X., Shang, X.-J., et al. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06590-4 · Cited by 4
“This trend has been paralleled by an increase in lifestyle-related diseases, including T2DM [3, 4].”
Magnesium Level and Related Factors in Type 2 Diabetes Mellitus: A Cross-Sectional Study
Konur, K., Polat, H. B., Karavar, E., & Ayaz, T. (2025) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/0118715303411661250721141050 · Cited by 4
Gómez, J. J. L., González-Gutiérrez, J., Pérez-López, P., Izaola-Jáuregui, O., Cebriá, Á., Asensio, L. E., Primo, D., Saavedra-Vasquez, M. A., Ramos-Bachiller, B., Rico, D., et al. (2025) · Nutrients · doi:10.3390/nu17203208 · Cited by 4
“These misconceptions frequently result in a carbohydrate intake that falls below the recommended percentage of total caloric value (%TCV), while the proportion of protein consumed tends to be relatively high, though not necessarily adequate in absolute terms [31].”
Seo, M., Suh, K., Park, H. K., & Cho, K. W. (2025) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2025.363 · Cited by 4
“For obese individuals, the approach to achieving weight loss is widely acknowledged to improve metabolic complications and reduce mortality rates [3,4].”
Challenges in the management of obesity
Smith, B. L., May, A., Lalani, F., Hasham, S., & Presnell, A. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.09.023 · Cited by 4
Currently Approved and Future Regimens for Metabolic Dysfunction-Associated Steatohepatitis
Abreu, E. S., Noureddin, M., Takahashi, H., Schattenberg, J. M., & Abdelmalek, M. F. (2026) · Clinics in Liver Disease · doi:10.1016/j.cld.2026.01.004 · Cited by 4
Galindo, R. J., Gudzune, K. A., Look, M., Lee, C. J., Benabbad, I., Cao, D., Meng, Q., & Mojdami, D. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2026.3274 · Cited by 4
Hsieh, T. Y. J., Yen, T., Hacker, M. R., Dottino, J. A., & Esselen, K. M. (2026) · Gynecologic Oncology · doi:10.1016/j.ygyno.2026.03.010 · Cited by 4
Zeng, X., Xing, Y.-H., Xiu-mei, M., Long, Y., Jiang, Z., & Xu, Y. (2025) · PLoS ONE · doi:10.1371/journal.pone.0319053 · Cited by 4
Nguyen-Hoang, N., Nazzal, M., Schneider, B. P., Trivedi, M. S., & Hertz, D. L. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104739 · Cited by 5
Pancreatic Exocrine Insufficiency After Metabolic and Bariatric Surgery
Bathobakae, L., Rivera, E., Mücahit, D., John, R., Atogwe, I. D., Phuu, P., Escobar, J., Bandaru, P. K. R., Cavanagh, Y., Ligresti, R., et al. (2025) · Digestive Diseases and Sciences · doi:10.1007/s10620-025-09325-z · Cited by 5
“Obesity is a chronic, multifactorial disease characterized by an abnormal or excessive accumulation of body fat that may impair health [1–4].”
InfluentialGallwitz, B., Aberle, J., Birkenfeld, A. L., KELLERER, M., Klein, H. H., Landgraf, R., Müller‐Wieland, D., Müssig, K., Nauck, M. A., Siegel, E. G., et al. (2025) · Diabetologie und Stoffwechsel · doi:10.1055/a-2592-7923 · Cited by 4
Evidence-Based Synthesis for Practice: Lifestyle Interventions in Type 2 Diabetes with Obesity
Wang, H., Chen, F., Zhang, Q., Chen, J., Zhang, W., Fang, L., & Xiong, P. (2025) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s550776 · Cited by 5
“20 Evidence confirms that high-intensity https://doi.org/10.2147/DMSO.S550776 Diabetes, Metabolic Syndrome and Obesity 2025:18 engagement with DSMES (eg, >10 hours over 6–12 months) is associated with significantly lower glycated hemoglobin and mortality rates.”
InfluentialLuo, C., Yu, X. F., Hua, L.-Y., Zeng, M.-Q., Xu, H., Duan, C., Xu, S., Da Yu, S. U. N., Ye, L., & He, D. (2025) · World Journal of Stem Cells · doi:10.4252/wjsc.v17.i11.111162 · Cited by 7
“Given their superior glycemic and weight-lowering effects, clinical guidelines recommend GLP-1RAs in combination with metformin and/or other agents for patients with T2DM requiring weight management to achieve maximum therapeutic efficacy[47,48].”
InfluentialPosicionamento sobre a Saúde Cardiometabólica ao Longo do Ciclo de Vida da Mulher – 2025
de Oliveira, G. M. M., de Almeida, M. C. C., Valério, C. M., Giuffrida, F. M. A., Espíndola, L. N., Izar, M. C. D. O., Marques-Santos, C., Freire, C. M. V., Albuquerque, C. J. D. M., Chagas, A. C. P., et al. (2025) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20250615 · Cited by 5
Tirzepatide vs. semaglutide: clinical decision-making in the GLP-1 landscape
Mondoh, A., Crotty, M., & le Roux, C. W. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2601060 · Cited by 3
The important role of comorbidities in the management of obesity
Barenbaum, S. R., Tchang, B. G., & Aronne, L. J. (2026) · Journal of the Endocrine Society · doi:10.1210/jendso/bvag012 · Cited by 5
Pharmacological interactions between asthma and T2DM therapies: clinical and metabolic implications
Matera, M. G., Page, C. P., Calzetta, L., Rogliani, P., & Cazzola, M. (2026) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2026.2632668 · Cited by 3
“ADA guidelines recommend GLP-1RAs and dual GIP/GLP-1RAs (e.g. tirzepatide) for T2DM with obesity, due to their dual metabolic efficacy [170].”
Hageen, A. W., Gadelmawla, A. F., Saleh, A. O., Abdallfatah, A., Reyad, M., El‐Nemr, A. F., Maihoub, O., Elsekhary, A., Eladawi, S., Ayalew, B. D., et al. (2026) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70222 · Cited by 3
Crowley, M. J., Lewinski, A. A., Yang, Q., Hatch, D., Palipana, A., Bosworth, H. B., Kaufman, B. G., Chatterjee, R., Pennington, G., Matters, D., et al. (2026) · Annals of Internal Medicine · doi:10.7326/annals-26-00132 · Cited by 5
Rahman, V. J., Becker, R., Gray, S., Holubkov, R., Loomis, J. F., & Barnard, N. D. (2025) · American Journal of Lifestyle Medicine · doi:10.1177/15598276251339396 · Cited by 3
Alali, A. O., Alanazi, A. F. A., Albarghash, M. A. M., Alruweli, R. N. A., Alanazi, M. B. H., Alanazi, I. F. B., Alrowaily, T. S. H., Alanazi, R. K. M., Alsel, B. T. A., Alenezi, F. N. M., et al. (2025) · Clinics and Practice · doi:10.3390/clinpract15070115 · Cited by 3
“Obese individuals are at increased risk for a spectrum of comorbidities, such as cardiovascular disease, hyperlipidemia, type 2 diabetes, and gallstone disease (cholelithiasis) [2].”
Hossain, M. U., Rahman, A., Hossain, M. S., Dey, S., Chowdhury, Z. M., Bhattacharjee, A., Ahammad, I., Hasan, M. K., Ahmed, I., Hosen, M. B., et al. (2025) · BMC Complementary Medicine and Therapies · doi:10.1186/s12906-025-04845-7 · Cited by 3
Jamali, A., Ram, N., Karim, S., Sattar, S., Rashid, M. S., & Islam, N. (2023) · International Journal of Community Medicine and Public Health · doi:10.18203/2394-6040.ijcmph20233433 · Cited by 3
Metadata
- Authors
- American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., Ekhlaspour, L., Garg, R., Khunti, K., Kushner, R. F., Lal, R., Lingvay, I., Matfin, G., Pandya, N., Pekas, E. J., Pilla, S. J., Polsky, S., Segal, A. R., Seley, J. J., Stanton, R. C., & Bannuru, R. R.
- ORCID
- ElSayed, Nuha A.
- McCoy, Rozalina G.
- Aleppo, Grazia
- Balapattabi, Kirthikaa
- Beverly, Elizabeth A.
- Briggs Early, Kathaleen
- Bruemmer, Dennis
- Echouffo-Tcheugui, Justin B.
- Ekhlaspour, Laya
- Garg, Rajesh
- Khunti, Kamlesh
- Kushner, Robert F.
- Lal, Rayhan
- Lingvay, Ildiko
- Pandya, Naushira
- Pekas, Elizabeth J.
- Pilla, Scott J.
- Polsky, Sarit
- Segal, Alissa R.
- Seley, Jane Jeffrie
- Stanton, Robert C.
- Bannuru, Raveendhara R.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2024-12-09
- Volume
- 48
- Issue
- Supplement_1
- Pages
- S167-S180
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC11635032
- OpenAlex
- W4405187634
- Cited by
- 236
- References
- 157
- Citations by year
- 2026: 102 · 2025: 119 · 2024: 9
- FWCI
- 13.44
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (K23DK121942)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Keywords
- obesity, weight management, type 2 diabetes, diabetes prevention, diabetes treatment, clinical guidelines
- MeSH terms
- Diabetes Mellitus, Type 2, Humans, Obesity, Standard of Care
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.